[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11201506445PA - C-3 alkyl and alkenyl modified betulinic acid derivatives useful in the treatment of hiv - Google Patents

C-3 alkyl and alkenyl modified betulinic acid derivatives useful in the treatment of hiv

Info

Publication number
SG11201506445PA
SG11201506445PA SG11201506445PA SG11201506445PA SG11201506445PA SG 11201506445P A SG11201506445P A SG 11201506445PA SG 11201506445P A SG11201506445P A SG 11201506445PA SG 11201506445P A SG11201506445P A SG 11201506445PA SG 11201506445P A SG11201506445P A SG 11201506445PA
Authority
SG
Singapore
Prior art keywords
hiv
alkyl
treatment
acid derivatives
betulinic acid
Prior art date
Application number
SG11201506445PA
Inventor
Jacob Swidorski
Yan Chen
Sing-Yuen Sit
Nicholas A Meanwell
Alicia Regueiro-Ren
Jie Chen
Zheng Liu
Richard A Hartz
Li Xu
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SG11201506445PA publication Critical patent/SG11201506445PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201506445PA 2013-02-25 2014-02-21 C-3 alkyl and alkenyl modified betulinic acid derivatives useful in the treatment of hiv SG11201506445PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361768630P 2013-02-25 2013-02-25
PCT/US2014/017688 WO2014130810A1 (en) 2013-02-25 2014-02-21 C-3 alkyl and alkenyl modified betulinic acid derivatives useful in the treatment of hiv

Publications (1)

Publication Number Publication Date
SG11201506445PA true SG11201506445PA (en) 2015-09-29

Family

ID=50288267

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201506445PA SG11201506445PA (en) 2013-02-25 2014-02-21 C-3 alkyl and alkenyl modified betulinic acid derivatives useful in the treatment of hiv

Country Status (15)

Country Link
US (1) US9249180B2 (en)
EP (1) EP2958930A1 (en)
JP (1) JP6186012B2 (en)
KR (1) KR20150121712A (en)
CN (1) CN105102468A (en)
AR (1) AR094876A1 (en)
AU (1) AU2014218754B2 (en)
BR (1) BR112015019590A2 (en)
CA (1) CA2902513A1 (en)
EA (1) EA027861B1 (en)
IL (1) IL240739A0 (en)
MX (1) MX2015010354A (en)
SG (1) SG11201506445PA (en)
TW (1) TW201444862A (en)
WO (1) WO2014130810A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
CA2981056A1 (en) * 2015-04-14 2016-10-20 ViiV Healthcare UK (No.4) Limited Methods of producing an hiv maturation inhibitor
EA038890B1 (en) 2015-11-02 2021-11-03 Блюпринт Медсинс Корпорейшн Inhibitors of ret
AR107512A1 (en) 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD TRITERPENOIDS MODIFIED IN C-3 AND C-17 AS HIV-1 INHIBITORS
UY37155A (en) 2016-03-17 2017-10-31 Blueprint Medicines Corp RET INHIBITORS
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
US10035789B2 (en) 2016-07-27 2018-07-31 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
WO2018044838A1 (en) * 2016-08-31 2018-03-08 Viiv Healthcare Company Combinations and uses and treatments thereof
CN106749486A (en) * 2016-11-30 2017-05-31 沈阳化工大学 A kind of oleanolic acid derivate and its application with ethylenediamine as linking arm
KR20200083969A (en) 2017-09-14 2020-07-09 피닉스 바이오테크놀러지 인코포레이티드. Methods and neuroprotective compositions for treating neurological conditions
IL285232B (en) 2017-09-14 2022-07-01 Phoenix Biotechnology Inc Compositions comprising oleandrin for treating viral infection
SI3773589T1 (en) 2018-04-03 2024-03-29 Blueprint Medicines Corporation Ret inhibitor for use in treating cancer having a ret alteration
EP4248960A3 (en) 2019-02-11 2024-01-03 Hetero Labs Limited Novel triterpene derivatives as hiv inhibitors
CN111362923A (en) * 2020-03-25 2020-07-03 魏威 Method for preparing RET inhibitor pracetib, intermediate of pracetib and preparation method of pracetib
CN111440151A (en) * 2020-03-25 2020-07-24 魏威 Method for preparing antitumor drug prasutinib
EP4009981B1 (en) 2020-03-31 2023-08-16 Phoenix Biotechnology, Inc. Method and compositions for treating coronavirus infection
RU2020130238A (en) 2020-03-31 2022-03-14 Феникс Байотекнолоджи, Инк. METHOD AND COMPOSITIONS FOR TREATMENT OF CORONAVIRUS INFECTION

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
US6369101B1 (en) * 1999-02-26 2002-04-09 Regents Of The University Of Minnesota Therapeutic method to treat herpes virus infection
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
JP2007529544A (en) 2004-03-17 2007-10-25 パナコス ファーマシューティカルズ， インコーポレイテッド Pharmaceutical salt of 3-O- (3 ', 3'-dimethylsuccinyl) betulinic acid
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
US20090105203A1 (en) 2006-10-16 2009-04-23 Myriad Genetics, Incorporated Compounds for treating viral infections
WO2009100532A1 (en) 2008-02-14 2009-08-20 Virochem Pharma Inc. NOVEL 17ß LUPANE DERIVATIVES
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
CA2801487C (en) 2010-06-04 2017-12-05 Bristol-Myers Squibb Company Modified c-3 betulinic acid derivatives as hiv maturation inhibitors
JP5755731B2 (en) 2010-06-04 2015-07-29 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Modified C-3 betulinic acid derivative C-28 amide as an HIV maturation inhibitor
MA34909B1 (en) * 2011-01-31 2014-02-01 Bristol Myers Squibb Co MODIFIED C-17 AND C-3 TRITERPENOIDS WITH INHIBITORY ACTIVITY OF HIV MATURATION
EP2670764B1 (en) * 2011-01-31 2015-09-02 Bristol-Myers Squibb Company C-28 amines of c-3 modified betulinic acid derivatives as hiv maturation inhibitors
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity

Also Published As

Publication number Publication date
AR094876A1 (en) 2015-09-02
CA2902513A1 (en) 2014-08-28
AU2014218754A1 (en) 2015-10-15
KR20150121712A (en) 2015-10-29
US9249180B2 (en) 2016-02-02
BR112015019590A2 (en) 2017-07-18
JP2016509062A (en) 2016-03-24
EA201591545A1 (en) 2015-12-30
US20140243298A1 (en) 2014-08-28
MX2015010354A (en) 2015-10-09
TW201444862A (en) 2014-12-01
EP2958930A1 (en) 2015-12-30
IL240739A0 (en) 2015-10-29
WO2014130810A1 (en) 2014-08-28
JP6186012B2 (en) 2017-08-23
CN105102468A (en) 2015-11-25
EA027861B1 (en) 2017-09-29
AU2014218754B2 (en) 2017-04-20

Similar Documents

Publication Publication Date Title
IL240739A0 (en) C-3 alkyl and alkenyl modified betulinic acid derivatives useful in the treatment of hiv
IL264541B (en) Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
HRP20181863T1 (en) Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
HK1217330A1 (en) N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b n--
HK1217326A1 (en) Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
HK1202553A1 (en) Lupane triterpenoid derivatives and pharmaceutical use thereof
PL3466425T3 (en) Use of glutarimide derivatives in the treatment of eosinophilic diseases
AP2015008814A0 (en) Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b